Merck Unveils HDL-Cholesterol Drug Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials are starting for HDL-cholesterol therapy combining extended-release niacin and anti-flushing compound and for Zocor combination.
You may also be interested in...
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Merck’s Niacin Combination Drug To Be Evaluated In Heart Protection Study 2
$79.2 mil. THRIVE study will evaluate niacin in combination with an investigational prostaglandin D2 blocker in 20,000 patients.